July 8, 2015
The National Cancer Center (NCC) announced on July 7 that it has initiated an investigator-initiated PI clinical study of the siRNA nucleic acid drug TDM-812, a complex drug formulation consisting of RPN2siRNA and surfactant-like peptide A6K, in patients with treatment-resistant...read more